Managing Adverse Events With BCL-2 and PI3K Inhibitors in CLL

Source: Smarter. Stronger. Together. Progressing Toward Optimal CLL Care Through Healthcare Professional and Patient Education
Download Slideset
Download this slideset for expert perspectives on best practices in identifying and managing key adverse events commonly associated with BCL-2 and PI3K inhibitors in patients with CLL.
Nicole Lamanna, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 174 KB
Released: March 17, 2022

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
CLL Society Logo
Supported by educational grants from
AbbVie Inc.
AstraZeneca
Eli Lilly and Company
Pharmacyclics LLC, an AbbVie Company
Janssen Biotech, Inc.
TG Therapeutics, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings